Navigation Links
Jennerex Closes $5 Million First Tranche of Series C Financing
Date:8/11/2009

SAN FRANCISCO, Aug. 11 /PRNewswire/ --Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced the first closing of a private placement financing with gross proceeds of US $5,123,521, exceeding the target of $5 million USD. A second closing is anticipated on or before September 15, 2009, with additional proceeds to be determined.

The net proceeds of the private placement will be used to continue advancing the Company's clinical development programs with the lead product JX-594. Key value creating trials include the following: initiation of a randomized Phase 3 liver cancer trial, completion of a Phase 2 colon cancer trial and a Phase 1 trial targeting lung cancer and other solid tumors. Proceeds will also be used for research and development, general corporate purposes and to augment working capital.

"We are again delighted by the enthusiastic support of existing shareholders, and also welcome several new shareholders to the Company," said David H. Kirn, M.D., President and CEO. "This funding, together with cash resources on hand, is expected to cover operations for the next 16 months, through the end of 2010, and specifically to fund the company through significant value inflection points, including completion of the above-mentioned Phase 1 and Phase 2 clinical trials," said Dr. Kirn.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. J
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
4. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
5. Micromet Closes $80.5 Million Public Offering of Common Stock
6. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
7. Signostics Closes Follow-On Financing of US$4 Million, Expands Board of Directors
8. NewLink Genetics Corporation Closes $7.5 Million Financing
9. Pharmaxis Closes Share Purchase Plan
10. China Biologic Products Closes the $9.6 Million Private Placement
11. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... (PRWEB) May 24, 2013 The Oklahoma ... And following its ravage, the mayor of Moore, one of ... new houses, said a report from cnn.com. Reaching out to ... victims complimentary Molderizer and Safe Shield to counter the looming ... report published on May 22, 2013, caused 24 deaths, My ...
(Date:5/23/2013)... Arbor, Mich. Every day, their baby stopped breathing, ... to his lungs. April and Bryan Gionfriddo watched helplessly, ... , "Quite a few doctors said he had a ... April Gionfriddo, about her now 20-month-old son, Kaiba. "At ... we would take it and run with it." , ...
(Date:5/23/2013)... Graphite Metallizing Corporation announces a ... in stainless steel pillow blocks. This series combines ... the application and installation versatility of pillow blocks. ... work exceptionally well when submerged in water, water-soluble ... as acids, alkalies, hydrocarbons, black liquor, and liquid ...
(Date:5/23/2013)... 2013 The maker community is a ... inventions. They focus on learning practical skills while applying ... toward bringing their ideas to life via crowdfunding. A ... on making projects using biology. Glowing Plant has worked ... make them glow with bioluminescence genes, and has now ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... 10 /PRNewswire-FirstCall/ - Mr. Pierre,Fitzgibbon, President and Chief ... "Company", TSX: ATB) today announced changes to the,management ... by Mr.,Richard Bordeleau, President of the Health & ... pursue news challenges. However, Mr. Bordeleau,will continue to ...
... Audio Webcast Tuesday, September 11, 2007, SAN DIEGO, ... announced today that Neurocrine Biosciences will,present at the Bear ... 11, 2007 at 10:30 a.m. Eastern Time (ET),/7:30 a.m. ... may be accessed on the Company,s website at, http://www.neurocrine.com ...
... the Treatment of Opioid ... ... (Nasdaq: NKTR ) presented results today at the American ... 1 trial of NKTR-118 (oral PEG-naloxol). NKTR-118 is Nektar,s,proprietary investigational ...
Cached Biology Technology:Atrium Innovations Announces Management Changes 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 2Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 3Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 4Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting 5
(Date:5/23/2013)... Neuron , the team reveal the interplay of ... funded by the Wellcome Trust and BBSRC. , ... we improve our perceptual abilities. While these changes can ... also affect the fidelity of that response. ... explains: "When you communicate with others, you can make ...
(Date:5/22/2013)... Screening Trial (NLST) investigators also conclude that the ... low-dose computed tomography (LDCT) versus chest X-ray (CXR) ... is achievable at experienced screening centers in the ... to share with their patients about the benefits ... today,s publication in the New England Journal ...
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... and accurately distinguish species based on a simple DNA ... in the war against a major global disease. ... Biodiversity Foundation, is pioneering the use of DNA "barcodes" ... spread lymphatic filariasis (LF), commonly known as elephantiasis. Using ...
... some kinds of memories for a lifetime. But when ... gray matter also creates temporary memories that help us ... memories exist. For decades, scientists have held that such ... imprecise over the course of several seconds. Now ...
... a practiced eye and Google Earth all played ... fossils that may shed light on the origins ... story, featuring University of Michigan paleontologists Philip Gingerich, ... of a segment on the award-winning television series ...
Cached Biology News:DNA barcoding of mosquito species deployed in bid to end elephantiasis 2DNA barcoding of mosquito species deployed in bid to end elephantiasis 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 4Some short-term memories die suddenly, no fading 2Google Earth aids discovery of early African mammal fossils 2Google Earth aids discovery of early African mammal fossils 3
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: